logo
Rare Allergy Triggered by K-Pop Dancing and Crab Consumption

Rare Allergy Triggered by K-Pop Dancing and Crab Consumption

Medscape20-05-2025

A 30-year-old man presented to the hospital with acute shortness of breath and generalised urticaria. He had no known preexisting conditions or allergies. The patient reported that his symptoms began shortly after eating crabs and engaging in vigorous physical activity while dancing to K-pop.
Further investigation revealed that he danced to fast-paced songs.
The case reported by Tianci Tang, of the School of Public Health, Zhejiang Chinese Medicine University, Hangzhou, China, and colleagues highlighted a rare medical condition.
The Patient and His History
The patient reported acute shortness of breath and generalised urticaria that had started 2 hours before admission. Four hours earlier, he had eaten crab and danced. After 2 hours of dancing, a large wheal appeared on the patient's chest.
Shortly thereafter, he experienced redness and swelling of the neck, followed by breathing difficulties. The patient denied any history of allergies. His medical, medication, family, social, drug, and travel histories were unremarkable.
Upon further questioning, the patient revealed that he had been dancing to the K-pop and BABYMONSTER's 'Batter Up,' indicating that the exercise had been intense and involved significant physical exertion.
Findings and Diagnosis
On admission, the patient's oxygen saturation in room air was 98%, and his heart rate was 112 beats/min. His respiratory rate, body temperature, and blood pressure were within normal limits. The patient was alert and fully oriented.
Examination revealed pharyngeal redness and congestion, involuntary trembling, regular abdominal softness, no pressure pain, and swelling in both lower limbs. Auscultation and percussion findings were unremarkable.
Shortly after admission, the patient developed an uncontrollable, violent cough, followed by vomiting. He was treated with 40 mg methylprednisolone sodium succinate in a physiologic salt 100 mg intravenous drip and 1 g vitamin C in a 500 mL intravenous drip of glucose.
Laboratory tests revealed normal cardiac, liver, and renal function.
On the basis of the World Health Organization criteria for allergic reactions, the patient was diagnosed with an exercise-induced food allergy.
During the night of admission, the patient's serum creatine kinase concentration rose to over 6000 IU/L. The patient was subsequently diagnosed with rhabdomyolysis after undergoing renal function tests. However, the patient's vital signs remained stable.
The treatment included adjusted medication doses, four bags of sodium chloride injection (500 mL/bag size) for hydration, and sodium bicarbonate injection.
After treatment, the patient's skin symptoms temporarily improved. However, 3 hours later, a skin cyclone reappeared at the end of the toes and glans penis; therefore, a single intravenous injection of furosemide (2 mL, 20 mg) was administered. The patient's allergic symptoms resolved completely 6-7 hours after admission.
Discussion
'Allergy combined with rhabdomyolysis is a multifactorial disease; to our knowledge, no prior reports exist of allergy as a direct cause of rhabdomyolysis. The patient in our case recovered completely after anti-allergy treatment, urine alkalinisation, and hydration,' the authors concluded.
However, diverse symptoms remain rare and are challenging to manage.
The prevalence of exercise-induced food allergies in Germany is approximately 0.02%. Reliable data on the frequency of concurrent rhabdomyolysis are unavailable.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Weather ‘definitely a factor' in death of New York hikers in Maine park
Weather ‘definitely a factor' in death of New York hikers in Maine park

Yahoo

time2 days ago

  • Yahoo

Weather ‘definitely a factor' in death of New York hikers in Maine park

Weather may be to blame for the deaths of two hikers, a father and daughter from New York, in a Maine state park this week, officials revealed Thursday. Esther Keiderling, 28, was found dead around 1 p.m. on Wednesday in a wooded area, Baxter State Park officials wrote in a social media post. Her father, Tim, 58, was found dead a day prior, around 2:45 p.m., near the summit of Mount Katahdin. Both Keiderlings, of Ulster Park, New York, left Abol Campground on Sunday to hike to the summit. They were last seen at around 10:15 a.m. That day, the weather forecast called for temperatures in the mid-30s on the mountain, with the summit obscured, said Park Director Kevin Adam. There was a 70% chance of rain on Sunday, the day both Keiderlings went missing, with winds ranging from 30 to 40 mph. "It would have been freezing rain, fog, and some snow for Sunday," Adam explained. 'Weather is definitely a factor in this incident.' A search for the pair began Monday morning after finding their vehicle still in the day-use parking lot. Park rangers searched several trails, including the Katahdin Tablelands, and found no sign of the father and daughter. The search expanded Tuesday with more than 30 game wardens looking for the pair. The Maine Forest Service and Army National Guard used helicopters to aid in the search. Tim Keiderling was found dead on Tuesday by a game warden and his K-9. Game wardens, park rangers and K-9 teams resumed the search for Esther Keiderling Wednesday. 'We understand that many of our social media followers share in our profound sadness for the family and friends of Tim and Esther Keiderling,' officials wrote in a Facebook post. 'We appreciate your support for their loved ones and the members of the search teams during this incredibly difficult time. Our thoughts and deepest condolences are with Tim and Esther Keiderling's family and friends.' Capitol Hill Republicans shoot down Mass. lawmaker's effort to subpoena Elon Musk R&B icon says brother made 'mockery' of his estranged son's cancer death Boston marathon raised $50M+ for charity in 2025, setting record Belmont man wanted in connection with road rage hatchet assault surrenders Harvard Medical School renames DEI office as university fights against Trump admin in court Read the original article on MassLive.

Sam's Club says it plans to remove synthetic dyes from private brand by end of 2025
Sam's Club says it plans to remove synthetic dyes from private brand by end of 2025

Yahoo

time2 days ago

  • Yahoo

Sam's Club says it plans to remove synthetic dyes from private brand by end of 2025

BENTONVILLE, Ark. (KNWA/KFTA) — Sam's Club announced on Thursday plans to eliminate more than 40 ingredients from its private label brand, Member's Mark, by the end of the year. The wholesale chain said in a news release that under the initiative, 'Made Without,' it will alter its food and beverage products to offer items without certain ingredients in order to cater to specific dietary preferences. In April, U.S. Health Secretary Robert F. Kennedy Jr. and Food and Drug Administration Commissioner Marty Makary announced plans to phase out several types of artificial, petroleum-based dyes used as food coloring in various snacks, drinks and desserts that line grocery shelves, mainly citing kids' health as the reason for the move. 'We take pride in the high-quality ingredients that go into our products, but what truly differentiates us are the ingredients we consciously leave out,' Julie Barber, chief merchant at Sam's Club, said. 'Our 'Made Without' commitment underscores our aspiration to be members' go-to destination for quality at a disruptive value. For us, it's about listening to our members and providing the items that resonate with their lifestyles.' Here is the list of ingredients Sam's Club plans to eliminate from its 'Made Without' products: Acesulfame-K (Acesulfame Potassium) (Ace-K) Acetylated Ester of Mono & Diglycerides (ACETEM) Artificial Flavors Aspartame Azodicarbonamide (ADA) Benzyl Alcohol Butylated hydroxy anisole (BHA) Butylated Hydroxytoluene (BHT) Butylparaben Certified Synthetic Colors/FD&C Colors Cocamide DEA Cyclamates Cyclopentasiloxane Cyclotetrasiloxane Dioctyl Sodium Sulfosuccinate (DSS) DMDM Hydantoin Ethyl Vanillin Formaldehyde Hexa, Hepta, Octa Esters of Sucrose High Fructose Corn Syrup Lactylated Esters of Mono & Diglycerides (OLEON) Methylparaben Neotame Phthalates Potassium Bisulfate Potassium Bisulfite Potassium Nitrate/Nitrite Propyl Gallate Propylparaben Saccharin (All) Simplesse Sodium Ferrocyanide Sodium Propionate Sucroglycerides Sucrose Polyester Talc Tertiary Butylhydroquinone (Except for our 35-pound food service frying oils) Toluene Sam's Club said it has already released cookies and other snacks without artificial colors. The retailer is also offering fresh sushi as part of its 'Made Without' program. In addition to Sam's Club, Tyson recently announced it planned to eliminate synthetic dyes from its products, according to CEO Donnie King. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

NeuroPace Secures Up to $75 Million in Debt Financing
NeuroPace Secures Up to $75 Million in Debt Financing

Yahoo

time3 days ago

  • Yahoo

NeuroPace Secures Up to $75 Million in Debt Financing

MOUNTAIN VIEW, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loan were used to fully repay NeuroPace's term loan with CRG Partners IV, L.P., with proceeds of the new revolving credit facility available for working capital needs and other corporate purposes. 'We are pleased to partner with MidCap Financial on this new credit facility, which provides non-dilutive capital at favorable terms that reduce our cash interest expense and support the continued growth of our business,' said Joel Becker, Chief Executive Officer of NeuroPace. 'The proceeds and improved structure provide us the financial strength and flexibility to continue expanding patient access to the RNS® System and to invest in key growth initiatives, including site-of-service expansion, new indications, direct-to-consumer programs, new product development and real-world evidence generation. We also want to thank CRG for their partnership and support over the past several years. They have been an excellent partner in the Company's development.' The Company's new loan agreement includes a maturity date of five years for both the term loan and revolving credit facility. The annual interest rate is equal to SOFR subject to a floor of 2%, plus (1) 5.5% under the term loan and (2) 3.75% under the revolving loan. Armentum Partners served as financial advisor to NeuroPace on the transaction. Additional detail regarding the foregoing financing is set forth in NeuroPace's Current Report on Form 8-K, filed today with the U.S. Securities and Exchange Commission. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. About MidCap Financial MidCap Financial is a middle-market focused, specialty finance firm that provides senior debt solutions to companies across all industries. As of March 31, 2025, MidCap Financial provides administrative or other services for approximately $55 billion of commitments*. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, Inc., pursuant to an investment management agreement. Apollo had assets under management of approximately $785 billion as of March 31, 2025, in credit, private equity and real assets funds. For more information about MidCap Financial, please visit For more information about Apollo, please visit *Including commitments managed by MidCap Financial Services Capital Management LLC, a registered investment adviser, as reported under Item 5.F on Part 1 of its Form ADV Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace's expectations, forecasts and beliefs regarding the use of proceeds from the term loan and revolving credit facility with MidCap Financial. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including those described more fully in the section titled 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 13, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. Investor Contact:Scott SchaperHead of Investor Relationssschaper@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store